UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) OCTOBER 6, 2006 -------------------------- CEPTOR CORPORATION -------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in Its Charter) DELAWARE -------------------------------------------------------------------------------- (State or Other Jurisdiction of Incorporation) 001-32496 11-2897392 -------------------------------------------------------------------------------- (Commission File Number) (IRS Employer Identification No.) 200 INTERNATIONAL CIRCLE, SUITE 5100 HUNT VALLEY, MARYLAND 21030-1350 -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (410) 527-9998 -------------------------------------------------------------------------------- (Registrant's Telephone Number, Including Area Code) NOT APPLICABLE -------------------------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ITEM 8.01 OTHER EVENTS. On October 6, 2006, CepTor Corporation (the "Company") issued a press release disclosing a certain communication it received from the United States Food and Drug Administration regarding its Investigational New Drug Application submitted for Myodur, the Company's proposed product for the treatment of Duchene muscular dystrophy. ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits EXHIBIT NO. DESCRIPTION ----------- ----------- 99.1 Press Release SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CEPTOR CORPORATION Date: October 6, 2006 By: /s/ William H. Pursley ------------------------------------ William H. Pursley Chairman and Chief Executive Officer